Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.
about
CT-P13: design, development, and place in therapyGut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.p53 mediates TNF-induced epithelial cell apoptosis in IBD.T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFαCell mediated immunity to fungi: a reassessment.Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease.The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Role of the xenobiotic receptor in inflammatory bowel disease.Infliximab in ulcerative colitis.Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.Preconditioning Enhances the Therapeutic Effects of Mesenchymal Stem Cells on Colitis Through PGE2-Mediated T-Cell Modulation
P2860
Q33803728-4DADA8CA-3C16-4CFC-8358-1AA7640FC967Q36132003-A5074AD9-ABAF-4701-A9F6-9EFA341DD07BQ36295461-D045BDBC-5EFA-4DDB-A4CE-675FCD371127Q36380447-C00B9430-E5FC-451C-B345-938D43EBD9E4Q37380844-A1021BDE-2124-4CCE-8920-5EB7BCE63B64Q38099727-F07B05CB-CFDE-4B75-BAC2-783618AD779CQ38207758-34C34396-0F24-4DED-A3E9-1E4BF8BDCF82Q38223249-E3C493CF-01F9-42C2-98F9-C0788FE2532DQ38365426-F76B157C-1703-48E8-8259-379ED7D00978Q38586029-721FCE66-C429-4E34-8245-68CE83A1F36FQ38937842-FA7148C1-0109-4385-A602-6C4698B3BD6BQ39018436-376877AB-807E-4CD4-B65D-F8B36B0547DAQ41564802-016DD0C2-911B-4A77-8F47-1B28D584BF00Q41860347-17288F18-5CB6-41EA-AAD9-6713C8A59609Q45928244-E0945E52-339B-4A39-B7A0-2C0DC3E39137Q47368079-5F5A9AB2-BE48-4716-A0B6-6678ACBAAA18Q58788690-A94699ED-70BC-427A-9C11-26F43B1D61ED
P2860
Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mode of function of biological ...... f inflammatory bowel diseases.
@en
type
label
Mode of function of biological ...... f inflammatory bowel diseases.
@en
prefLabel
Mode of function of biological ...... f inflammatory bowel diseases.
@en
P2860
P1476
Mode of function of biological ...... f inflammatory bowel diseases.
@en
P2093
Arthur Kaser
Herbert Tilg
P2860
P304
P356
10.1517/14712598.7.7.1051
P407
P577
2007-07-01T00:00:00Z